Aluminium phosphate is included in the vaccine as an adjuvant. Adjuvants are substances included in certain vaccines to accelerate, improve and/or prolong the protective effects of the vaccines.
The other components are:phenol, water for injection.
Appearance of the product and contents of the package
Triaxis is presented as an injectable suspension in a pre-filled syringe (0.5 ml):
It contains a natural rubber latex derivative (latex) in the stopper at the end of the pre-filled syringe.
Only some package sizes may be marketed.
The normal appearance of the vaccine is a white and turbid suspension, which may sediment during storage. After proper agitation, the liquid has a uniform white appearance.
Holder of the marketing authorization and manufacturer responsible
The holder of the marketing authorization is:
Sanofi Winthrop Industrie
82 avenue Raspail
94250 Gentilly
France
The manufacturer responsible is:
Sanofi Winthrop Industrie
1541 avenue Marcel Mérieux
69280 Marcy l’Etoile
France
or
Sanofi Winthrop Industrie
Voie de l’Institut – Parc Industriel d’Incarville
B.P 101
27100 Val de Reuil
France
or
SANOFI-AVENTIS ZRT
Campona U.1 (Harbor Park ) - Budapest - 1225 - Hungary
Local representative
sanofi-aventis, S.A.
C/ Rosselló i Porcel, 21
08016 Barcelona
Spain
Tel: +34 93 485 94 00
This medicinal product has been authorized in the EEA Member States under the following names:
Austria, Germany: | Covaxis |
Belgium, Denmark, Finland, France, Greece, Ireland, Italy, Luxembourg, Norway, Portugal, Spain, Sweden, Netherlands: | Triaxis |
Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, Slovenia, United Kingdom (Northern Ireland): | Adacel |
Date of the last review of this leaflet:March 2023
The detailed information of this medicinal product is available on the website of the Spanish Agency of Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
This information is intended solely for healthcare professionals:
Instructions for use
In the absence of compatibility studies, Triaxis should not be mixed with other medicinal products.
Biological parenteral products must be visually inspected to detect foreign particles and/or discoloration before administration. If these conditions occur, the product should not be administered.
The needle should be tightened firmly in the end of the pre-filled syringe by a 90-degree turn.
The stopper should not be replaced on the needles.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.